Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

1. The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma

   Azat Karabekov, Vadim Kemaikin, Zhandos Burkitbayev +15

   МақолаMultiple Myeloma Research and TreatmentsJournal of Clinical Medicine20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.015051

2. Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

   Amr Ali Mohamed Abdelgawwad El‐Sehrawy, Ghaleb Oriquat, Sokhib Saidov +5

   МақолаCAR-T cell therapy researchClinica Chimica Acta20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.017391